Clinical trial
Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment
NCT06247605 is registered in ClinicalTrials.gov with Advenchen Laboratories Nanjing Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment
- Lead sponsor
- Advenchen Laboratories Nanjing Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 26, 2023
- Completion date
- July 31, 2029
- Enrollment
- 243 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.